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Abstract
Background: The seven-valent pneumococcal conjugate vaccine (PCV) was introduced in England in September 2006,
changing to the 13-valent vaccine in April 2010. PCV impact on invasive pneumococcal disease (IPD) has been extensively
reported, but less described is its impact on the burden of pneumonia, sepsis and otitis media in the hospital.
Methods: Using details on all admissions to hospitals in England, we compared the incidence of pneumococcal-specific
and syndromic disease endpoints in a 24-month pre-PCV period beginning April 2004 to the 24-month period ending
March 2015 to derive incidence rate ratios (IRRs). To adjust for possible secular trends in admission practice, IRRs were
compared to the IRRs for five control conditions over the same period and the relative change assessed using the
geometric mean of the five control IRRs as a composite, and individually for each control condition to give the
min-max range. Relative changes were also compared with IRRs for IPD from the national laboratory database. The
effect of stratifying cases into those with and without clinical risk factors for pneumococcal infection was explored.
Results: Relative reductions in pneumococcal pneumonia were seen in all age groups and in those with and without
risk factors; in children under 15 years old reductions were similar in magnitude to reductions in IPD. For pneumonia of
unspecified cause, relative reductions were seen in those under 15 years old (maximum reduction in children under
2 years of 34%, min-max: 11–49%) with a relative increase in 65+ year olds most marked in those with underlying risk
conditions (41%, min-max: 0–82%). Reductions in pneumococcal sepsis were seen in all age groups, with the largest
reduction in children younger than 2 years (67%, min-max 56–75%). Reductions in empyema and lung abscess were
also seen in under 15 year olds. Results for other disease endpoints were varied. For disease endpoints showing an
increase in raw IRR, the increase was generally reduced when expressed as a relative change.
Conclusions: Use of a composite control and stratification by risk group status can help elucidate the impact of PCV
on non-IPD disease endpoints and in vulnerable population groups. We estimate a substantial reduction in the
hospitalised burden of pneumococcal pneumonia in all age groups and pneumonia of unspecified cause, empyema
and lung abscess in children under 15 years of age since PCV introduction. The increase in unspecified pneumonia in
high-risk 65+ year olds may in part reflect their greater susceptibility to develop pneumonia from less pathogenic
serotypes that are replacing vaccine types in the nasopharynx.
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Background
Streptococcus pneumoniae is a common gram-positive
bacterial pathogen with more than 90 identified serotypes
that may reside in the nasopharynx of healthy individuals.
It can cause diseases such as otitis media and pneumonia
if it spreads to adjacent organs. If the bacteria enter the
bloodstream, they cause invasive pneumococcal disease
(IPD) manifesting as bacteraemic pneumonia, meningitis
or other clinical presentations. Pneumococci are transmit-
ted by direct contact with respiratory secretions from both
healthy carriers and patients [1].
The burden of disease is not evenly distributed, with
those individuals with certain chronic conditions (immu-
nosupression, cochlear implants, asthma, diabetes,
alcoholism, chronic diseases of the lungs, heart, liver,
kidneys) at a much greater risk of infection [2].
Many developed countries have implemented a
pneumococcal vaccination programme targeting differ-
ent sectors of the population to protect against a
number of the most prevalent serotypes. In England, the
23-valent polysaccharide vaccine (PPV23) was first
recommended for those in clinical risk groups in 1992, then
extended to elderly cohorts in a step-wise manner, eventu-
ally being offered to all individuals aged 65+ years in 2003.
Uptake for 2014–2015 was 69.8% of eligible elderly individ-
uals [3]. The seven-valent conjugate vaccine (PCV7) was
first offered to all infants in September 2006 as a 2 + 1
schedule (at 2, 4 and 12 months), with a catch-up campaign
for children up to 2 years old. PCV7 was replaced in April
2010 by the 13-valent conjugate vaccine (PCV13) on the
same schedule but without a catch-up campaign.
Analyses in England have demonstrated the effectiveness
[4] and population impact of the sequential PCV7 and
PCV13 vaccination programme in infants through the re-
duction of vaccine-type carriage [5, 6] and IPD caused by
the serotypes targeted by the vaccines [7, 8]. The impact of
this programme has also been demonstrated in terms of
indirect protection against IPD provided to unvaccinated
cohorts, though serotype replacement with non-vaccine
types has reduced the overall impact on IPD [7, 8].
We present an analysis of the estimated direct and indir-
ect impact of the PCV programme on hospital-diagnosed
pneumonia, sepsis and otitis media on all ages using
Hospital Episodes Statistics (HES) data from 2004–2005
to 2014–2015. We compare the disease trends for these
outcomes to trends for five control conditions unlikely to
be affected by the PCV vaccination to infer both direct
and indirect impact of the PCV programme.
Methods
Identification of cases
Public Health England has access to the HES database.
This electronic database contains data on all episodes of
hospital care in England. An episode is defined as a
continuous period of care administered within a particu-
lar consultant specialty at a single hospital provider.
HES uses the International Statistical Classification of
Diseases and Related Health Problems – 10th Revision
(ICD-10) classification to record diagnoses, of which
there are up to 20 fields available to clinicians, and can
therefore provide information on the burden of hospita-
lised disease due to different pathogens or syndromes in
England. We extracted data from HES for the period
April 2004 to March 2015 for all admissions with a
pneumonia, sepsis or otitis media ICD-10 code in any
diagnosis field for individuals in seven age groups: less
than 2 years old, 2–4 years, 5–14, 15–24, 25–44, 45–64
and 65+. The main analysis was restricted to admis-
sions with an ICD-10 code of interest in the first
diagnosis field, as this field indicates the primary
cause of the admission. Outpatient appointments and
emergency room consultations were not available. Ad-
missions were allocated to a HES data year (April to
March) using the date of discharge.
Our analysis of the impact of PCV on pneumonia fo-
cused on pneumococcal pneumonia (J13) and pneumo-
nia of unspecified causative organism (J18). J13 is a
bacterial pneumonia for which the cause is identified as
the pneumococcus. J18 is the most common of the
pneumonia diagnoses and has a mixed but unknown
aetiology. Respiratory infections mentioning pneumonia
associated with influenza or other viruses (J09-12) or
other specific bacterial causes of pneumonia (J14-J17)
were excluded We also considered the impact on other
respiratory conditions in which the pneumococcus can
have a causative role, namely empyema (J869) and ab-
scess of lung with pneumonia (J851). We identified sep-
sis diagnoses using the list of ICD-10 codes reported in
a cluster-randomised trial assessing the impact of
PCV10 on suspected invasive pneumococcal disease in
Finland [9], with pneumococcal-specific sepsis identified
using the diagnosis codes of A403, B953, G001 and
M001 and non-specific sepsis identified using the diag-
nosis codes A409, A419, A491, A499, B955, G009, M009
and I301. We identified otitis media using the H65, H66
and H67 ICD-10 codes, and we also identified a
subgroup of otitis media cases with procedure codes
relating to the insertion, removal or maintenance of ven-
tilation tubes through the tympanic membrane using
the Office of Population Censuses and Surveys, Clas-
sification of Surgical Operations and Procedures-4th
revision (OPCS-4) procedure codes D151, D202 and
D203 to assess the impact of the PCV programme on
recurrent acute otitis media. The ICD-10 codes used
to identify admissions are listed in Additional file 1:
Table S1. Repeat admissions within 90 days in the
same individual and with the same ICD-10 code in
the first field were considered to be the same disease
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episode. Incidence per 100,000 person-years was esti-
mated using mid-year population estimates for Eng-
land for 2004 to 2015 from the Office for National
Statistics as the denominator [10].
Identification of risk groups
Risk groups were identified using ICD-10 codes for
comorbidities found to increase the risk of pneumo-
coccal infection in any of the 20 diagnosis fields [2]
(immunosupression, cochlear implants, asthma, dia-
betes, alcoholism, and chronic diseases of the lungs,
heart, liver and kidneys; all ICD-10 codes are listed in
Additional file 1: Table S2).
Assessing the impact of the PCV programme
Using reports from diagnostic laboratories in England
and Wales to the national surveillance centre at Public
Health England, we compared trends in annual hospita-
lisations for each disease endpoint to the incidence of
IPD diagnosed by culture of S. pneumoniae from a nor-
mally sterile site, or by antigen detection or polymerase
chain reaction in cerebrospinal or pleural fluid. The
IPD laboratory data were adjusted for the improve-
ments in the efficiency of laboratory reporting of bac-
teraemias up to 2009–2010, as well as for reports with
missing age information [7, 8]. Incidence per 100,000
person-years for laboratory-confirmed IPD was esti-
mated using mid-year population estimates for England
and Wales for 2004 to 2015 from the same source as
above [10]. We estimated the change in incidence for
laboratory-confirmed IPD and each hospitalised disease
endpoint by calculating incidence rate ratios (IRRs)
using two defined time periods: the pre-PCV era (1
April 2004–31 March 2006) to match the same
calendar period in the post-PCV era (1 April 2013–31
March 2015), which was the most recent 2-year time
period in the dataset at the time of extraction.
To assess the robustness of our estimates of the IRRs,
we performed a sensitivity analysis by calculating the
IRRs for each disease endpoint but expanding the num-
ber of ICD-10 fields to the first three diagnoses and then
using all diagnoses available, while selection of controls
remained unchanged.
To account for biases arising from potential secular
trends in admission practice over the study period, the
IRRs of each disease endpoint were compared to the
IRRs of five control conditions that should not be af-
fected by changes in the introduction of the PCV
programme [11]. These were urinary tract infections,
infections of the skin and subcutaneous tissue, disor-
ders of the thyroid gland, diseases of the blood, and
fractures. These conditions were selected a priori with
the criteria that they were not caused by the pneumo-
coccus; not the focus of other public health
interventions; and with a large case burden with a simi-
lar age distribution of cases to the pneumococcal dis-
ease outcomes. We took admissions with the
appropriate ICD-10 code in the first diagnosis code of a
patient's episode (ICD-10s listed in Additional file 1:
Table S3). We excluded admissions for the control con-
ditions if one of the concurrent diagnoses was for one
of the studied diseases listed in Additional file 1: Table
S1. Readmissions within 90 days with the same ICD-10
code in the first field were considered to be the same
disease episode.
We calculated the age-specific ratio of the IRRs (de-
noted rIRR) for each disease over each control condition.
This ratio was used to help assess the impact of the
PCV programme as follows:
 Equal to 1 implies no difference in activity between
the disease endpoint and the control condition.
 Greater than 1 implies an increase in pneumococcal
disease incidence post-PCV greater than that seen in the
control, or a decrease less than that seen in the control.
 Less than 1 implies a decrease in pneumococcal disease
incidence post-PCV greater than that seen in the con-
trol, or an increase less than that seen in the control.
In addition, the age-specific IRRs of the disease
endpoints were compared to a composite control, cal-
culated using the geometric mean of the age-specific
IRRs of all five control conditions. The rIRR using
the composite control is presented along with the
minimum and maximum rIRRs calculated for each of
the five control conditions separately as an indicator
of uncertainty. We used the rIRR measure to estimate
the change in the absolute number of hospitalisations
for each disease endpoint attributable to the PCV
programme since April 2007, the first complete HES
data year after vaccine introduction, by assuming that
the IRR of each disease endpoint would have mir-
rored that of the composite control in the absence of
the PCV programme.
In assessing the impact of the PCV programme on
pneumonia by risk group status, since the size of the de-
nominator population by age group and year with and
without risk factors was not accurately known, we used
the raw numbers of admissions to calculate case ratios
for the pneumonia outcomes and the control conditions
and then derived the ratio of the two case ratios (termed
adjusted case ratios).
We did not compare the IRR of laboratory-reported
IPD to the control conditions from HES because the
IPD data from laboratories are not subject to the same
secular trends as the HES data and were already
corrected for trends in ascertainment of laboratory-
confirmed pneumococcal bacteraemias [7, 8].
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Results
Case numbers
The burden of pneumonia with unspecified causative or-
ganism across all ages (1,683,478 cases) was much larger
than that of pneumococcal pneumonia (30,459 cases,
Table 1). For sepsis cases, 97% (297,052/304,714) were
attributed to non-specific sepsis diagnoses, with
pneumococcal sepsis causing a small percentage (3%,
7976/304,714). More than 79% of all sepsis diagnoses
were sepsis with unspecified organism (ICD-10:
A419). Of the 408,999 otitis media admissions over
the study period, 74% (108,598/408,999) were for
nonsuppurative otitis media, with 315,908 of all
otitis media cases with tympanostomies (77% of the
total). A full breakdown by age of the number cases
for each ICD-10 diagnosis is available in Additional
file 1: Table S4.
Individuals in risk groups identified by presence of co-
morbidities made up 66% of all pneumonia cases, 47% of
all other respiratory cases, 66% of all sepsis cases and 5%
of all otitis media cases.
4% of all pneumococcal pneumonia, pneumonia of
unspecified causative organism, lung abscess and
empyema cases identified by the first ICD-10 code
had concurrent sepsis codes and 0.1% had otitis
media codes in the remaining ICD-10 codes. We
found that 17% of all sepsis cases and 0.4% of all
otitis media cases identified by the first ICD-10 code
had concurrent pneumonia, empyema or lung abscess
with pneumonia codes in the remaining ICD-10
codes. Information on the case numbers for those
individuals with diagnoses for more than one
pneumococcal disease endpoint is provided in
Additional file 1: Table S5.
Changes in the incidence of pneumococcal-specific and
syndromic disease, compared with IPD
Observed trends in incidence among the different
respiratory disease endpoints did not consistently fol-
low the reduction observed in the incidence of
laboratory-reported IPD (Fig. 1). Disease trends for
pneumococcal pneumonia were broadly similar to
those reported for IPD for individuals up to 15–24
years of age, though not in older individuals, where
IPD rates declined but pneumococcal pneumonia
admissions did not. Reductions in admissions with
pneumonia of unspecified causative organism were
only evident in children up to 15 years of age; in the
65+ years age group the annual incidence of admis-
sion for J18 increased from 829 to 1787 per 100,000
person-years between 2004–05 and 2014–15 respect-
ively. Reductions in admissions for empyema were
also seen in children up to 15 years of age but not
for admissions for lung abscess with pneumonia.
The incidence of pneumococcal sepsis declined from
20 to 7 per 100,000 person-years in the < 2 years age
group between 2004–05 and 2014–15; declines were also
seen in 2–14 year olds. In all age groups the incidence of
non-specific sepsis increased over the same period
(Fig. 2). The incidence of otitis media with tympanost-
omy showed a consistent decline in children under
15 years old, though a similar decline was not seen for
all otitis media diagnoses, or in older age groups.
When added together the incidence of pneumococcal
pneumonia and pneumococcal sepsis was lower than
that of laboratory-confirmed IPD in all age groups
(Figs. 1 and 2).
Table 2 shows both the IRRs for all studied disease
endpoints compared with the IRR for IPD as well as the
ratio of the IRRs for the disease endpoints compared
with the composite control. The incidence of IPD for
children younger than 2 years declined by 72% (95%
confidence interval (CI) 68–75%) over the study period.
For this age group the reduction in the incidence of
pneumococcal pneumonia was 80% (95% CI 74–85%);
reductions for other disease endpoints were recurrent
acute otitis media requiring tympanostomy 47% (95% CI
44–50%), pneumonia of unspecified causative organism
31% (95% CI 29–33%) and empyema 54% (95% CI 40–
65%). Reductions in pneumococcal pneumonia were also
seen in age groups from 2–44 years, but increases were
observed in individuals aged 45+ years. No reductions in
incidence for this age group were seen for the other dis-
ease endpoints.
Table 1 The number of cases of pneumonia, sepsis and otitis
media in England and the percentage of those cases for individuals
in clinical risk groups, from April 2004 through March 2015
ICD-10 Total number of cases
(% cases in risk groups)
Pneumonia
Pneumococcal pneumonia 30,459 (58%)
Pneumonia (unsp. organism) 1,683,478 (66%)
Total 1,713,937 (66%)
Remaining two respiratory conditions
Empyema 23,434 (45%)
Lung abscess with pneumonia 2616 (58%)
Total 26,050 (47%)
Sepsis
Any sepsis 304,714 (66%)
Any non-specific sepsis 297,052 (67%)
Any pneumococcal sepsis 7976 (43%)
Otitis media
All otitis media 408,999 (5%)
Otitis media, tympanostomy 315,908 (4%)
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No significant reduction was seen in the incidence of
lung abscess with pneumonia for any age group. In con-
trast, admissions for empyema and pneumonia of un-
specified causative organism reduced in all age groups
under 15 years of age (Table 2).
Using the composite control to estimate the ratio of IRRs
A reduction in the incidence of pneumococcal pneumonia
compared to the composite control was observed in the <
2 years age group, in addition to reductions for all other
endpoints except non-specific sepsis (Table 2 and Fig. 3).
Compared to the composite control, reductions in the
incidence of pneumococcal pneumonia and pneumococ-
cal sepsis were seen in all age groups, though not when
compared with each control condition individually (as
evidenced by a value > 1 in the min, max range).
A favourable impact on pneumonia with unspecified
causative organism was only evident in individuals aged
less than 15 years, as the incidence of this endpoint in-
creased more than the composite control for older age
groups (Additional file 1: Figure S7). Reductions in the
incidence of otitis media with tympanostomy were lar-
gest in children under 2 years of age (rIRR 0.51, min-
max 0.39–0.69). Reductions were also seen at older ages,
though not always in excess of those seen in all five of
the control conditions.
In general, for those disease outcomes showing an in-
crease in the raw IRR over the study period, the IRR
when compared with the IRR of the composite control
was lower.
Sensitivity analysis
The magnitude of the rIRR varied with the number of ICD-
10s used to identify each condition of interest. Using only
the first ICD-10 code suggests that the incidence of
pneumococcal pneumonia for the 65+ age group decreased
by 13% (min-max -34–3%) relative to the composite con-
trol (Table 2), though expanding the number of diagnosis
codes to the first three suggests a decrease in incidence of
23% (min-max 9–41%), and expanding the number of diag-
nosis codes for all suggests a decrease in incidence of 25%
(min-max 11–43%) (Additional file 1: Table S6). In younger
age groups, use of additional ICD-10 codes had little impact
(25–44 years) or lessened the relative reduction in
pneumococcal pneumonia (<25 years). For pneumonia of
unspecified cause, increasing the number of ICD-10 codes
generally increased the rIRR.
Changes in pneumococcal pneumonia and pneumonia
due to unspecified organism by risk group
To improve the understanding regarding the observed
increase in unspecified pneumonia in older age groups,
Fig. 1 Comparison of the incidence per 100,000 of laboratory-confirmed IPD (plotted in red, right-hand axes) with the incidence per 100,000 of
respiratory disease endpoints (left-hand axes)
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the data were split into those with and without ICD
codes indicating a risk group. Table 3 shows both the
raw case ratios and case ratios adjusted using the
composite control for risk and non-risk groups for
pneumococcal pneumonia and pneumonia of unspeci-
fied causative organism. For pneumococcal pneumo-
nia, significant reductions were seen in adjusted case
ratios in risk and non-risk groups of all ages (Add-
itional file 1: Figures S8, S10). For unspecified pneu-
monia, increases in raw case ratios were found mainly
among those in clinical risk groups (Additional file 1:
Figures S9, S11), but as there was also an increase
among the controls (Additional file 1: Table S8), there
is a marked difference between the raw and adjusted
case ratios. The adjusted case ratios in younger age
groups were broadly similar between risk and non-
risk groups up to the 5–14 years group, but there is
a marked divergence in the older age groups.
To put the changes in overall disease trends com-
pared to the composite control into some context, we
estimated that the total hospitalised burden of
pneumococcal pneumonia reduced by 4611 cases for
all ages from April 2007 to March 2015, with large
reductions in the 65+ years age group (1917 cases)
and in children under 15 years of age (1315 cases).
Cases of otitis media with tympanostomy reduced by
30,649, 83% of which (25,565) were in children aged
< 15 years. We estimated a reduction of 19,712 cases
for pneumonia of unspecified organism for the same
age group, though this was counterbalanced by an
estimated increase of 251,894 cases for the 65+ year
age group. Further details of the estimated net change
in the number of cases since April 2007 can be found
in Table 4.
Discussion
Our national study shows that the PCV programme in
England has been associated with significant reductions
in hospital admissions across a range of non-specific
disease endpoints in the age groups targeted for vaccin-
ation. The endpoints chosen were ones in which the
pneumococcus is likely to have a causative role, although
the percentage contribution of pneumococcal infection
to these syndromes, and the serotype distribution,
cannot be directly determined.
This is the first study to investigate the impact of the
PCV programme on hospital admissions for a wide
range of pneumococcal-specific and syndromic disease
endpoints across all ages in England. In addition, we
sought to improve the interpretation of our impact
analyses by comparing with changes in control condi-
tions to allow for biases generated by secular trends in
Fig. 2 Comparison of the incidence per 100,000 of laboratory-confirmed IPD (plotted in red, right-hand axes) with the incidence per 100,000 of
sepsis endpoints and otitis media endpoints (left-hand axes)
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Table 2 The incidence rate ratios compare incidence between the pre-PCV era (1 April 2004–31 March 2006) and post-PCV era (1
April 2013–31 March 2015) for each disease endpoint. Also shown is ratio of incidence rate ratios (rIRRs) for each disease endpoint
compared with the composite control, with the maximum and minimum denoting the range of the individual rIRRs using each of
the five control conditions separately
Disease endpoint IRR post pre-vaccination
(95% CI)
rIRR disease endpoint, composite
control [min, max]
<2 years
IPD 0.28 (0.25–0.32)
Pneumococcal pneumonia 0.20 (0.15–0.26) 0.19 [0.15, 0.25]
Pneumonia (unsp. organism) 0.69 (0.67–0.71) 0.66 [0.51, 0.89]
Empyema 0.46 (0.35–0.60) 0.44 [0.34, 0.59]
Lung abscess with pneumonia 0.50 (0.17–1.50) 0.49 [0.38, 0.65]
Non-specific sepsis 2.89 (2.72–3.06) 2.79 [2.15, 3.73]
Pneumococcal sepsis 0.34 (0.28–0.40) 0.33 [0.25, 0.44]
Otitis media 0.78 (0.76–0.81) 0.76 [0.58, 1.01]
Otitis media with tympanostomy 0.53 (0.50–0.56) 0.51 [0.39, 0.69]
2–4 years
IPD 0.29 (0.24–0.34)
Pneumococcal pneumonia 0.42 (0.31–0.56) 0.47 [0.36, 0.65]
Pneumonia (unsp. organism) 0.72 (0.70–0.74) 0.80 [0.62, 1.11]
Empyema 0.51 (0.41–0.63) 0.57 [0.44, 0.79]
Lung abscess with pneumonia 0.63 (0.28–1.44) 0.70 [0.54, 0.98]
Non-specific sepsis 2.28 (2.04–2.55) 2.54 [1.95, 3.52]
Pneumococcal sepsis 0.48 (0.34–0.68) 0.53 [0.41, 0.74]
Otitis media 0.82 (0.81–0.84) 0.92 [0.70, 1.27]
Otitis media with tympanostomy 0.79 (0.77–0.81) 0.88 [0.68, 1.22]
5–14 years
IPD 0.27 (0.23–0.31)
Pneumococcal pneumonia 0.34 (0.25–0.46) 0.31 [0.27, 0.41]
Pneumonia (unsp. organism) 0.73 (0.70–0.75) 0.67 [0.59, 0.87]
Empyema 0.46 (0.38–0.56) 0.43 [0.37, 0.56]
Lung abscess with pneumonia 0.45 (0.17–1.20) 0.42 [0.37, 0.55]
Non-specific sepsis 2.18 (1.98–2.40) 2.02 [1.76, 2.63]
Pneumococcal sepsis 0.79 (0.55–1.14) 0.73 [0.64, 0.96]
Otitis media 0.80 (0.78–0.81) 0.74 [0.64, 0.96]
Otitis media with tympanostomy 0.78 (0.77–0.80) 0.72 [0.63, 0.94]
15–24 years
IPD 0.29 (0.25–0.34)
Pneumococcal pneumonia 0.57 (0.45–0.72) 0.50 [0.40, 0.69]
Pneumonia (unsp. organism) 1.18 (1.13–1.23) 1.04 [0.84, 1.43]
Empyema 0.90 (0.72–1.11) 0.79 [0.64, 1.09]
Lung abscess with pneumonia 1.15 (0.59–2.23) 1.01 [0.82, 1.39]
Non-specific sepsis 1.87 (1.74–2.02) 1.65 [1.33, 2.27]
Pneumococcal sepsis 0.85 (0.54–1.33) 0.74 [0.60, 1.03]
Otitis media 0.86 (0.81–0.90) 0.75 [0.61, 1.04]
Otitis media with tympanostomy 0.85 (0.80–0.92) 0.75 [0.61, 1.04]
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admission practice. We also used as a benchmark
changes in overall IPD incidence, which given the
specificity of this outcome is likely to represent a max-
imal impact when compared with less specific disease
endpoints such as all-cause pneumonia.
The reduction in admissions for pneumonia of
unspecified organism in children under 5 years of age
(which comprises more than 90% of all pneumonia
admissions in this age group) is similar to that in studies
in Sweden [12, 13], Uruguay [14], Scotland [15] and
southern Israel [16], where reductions ranging from 19
to 32% following the implementation of sequential
PCV7/PCV13 programmes have been reported. The
consistency of these observations in different settings
suggests a causal association with PCV7/PCV13 use.
The reductions observed in pneumonia admissions in
vaccine-eligible children post-licensure are greater than
suggested by the pre-licensure trial of PCV7 in the USA
in which clinically diagnosed pneumonias were only
reduced by 4.3% [17]. Unlike the US trial, our study was
restricted to pneumonias requiring hospital admission.
As the contribution of the pneumococcus to hospital-
admitted pneumonias in children is likely to be higher
than in those not admitted, the percentage reduction in
Table 2 The incidence rate ratios compare incidence between the pre-PCV era (1 April 2004–31 March 2006) and post-PCV era (1
April 2013–31 March 2015) for each disease endpoint. Also shown is ratio of incidence rate ratios (rIRRs) for each disease endpoint
compared with the composite control, with the maximum and minimum denoting the range of the individual rIRRs using each of
the five control conditions separately (Continued)
Disease endpoint IRR post pre-vaccination
(95% CI)
rIRR disease endpoint, composite
control [min, max]
25– 44 years
IPD 0.35 (0.32–0.37)
Pneumococcal pneumonia 0.82 (0.74–0.90) 0.68 [0.52, 0.82]
Pneumonia (unsp. organism) 1.34 (1.31–1.36) 1.11 [0.86, 1.34]
Empyema 1.33 (1.19–1.48) 1.11 [0.85, 1.33]
Lung abscess with pneumonia 2.09 (1.54–2.83) 1.74 [1.34, 2.10]
Non-specific sepsis 2.14 (2.05–2.23) 1.78 [1.37, 2.15]
Pneumococcal sepsis 0.84 (0.68–1.04) 0.70 [0.54, 0.84]
Otitis media 0.98 (0.94–1.02) 0.82 [0.63, 0.98]
Otitis media with tympanostomy 0.97 (0.93–1.02) 0.81 [0.62, 0.98]
45–64 years
IPD 0.50 (0.48–0.53)
Pneumococcal pneumonia 1.21 (1.12–1.30) 0.91 [0.69, 1.03]
Pneumonia (unsp. organism) 1.90 (1.87–1.93) 1.44 [1.09, 1.63]
Empyema 1.41 (1.30–1.53) 1.07 [0.81, 1.21]
Lung abscess with pneumonia 2.13 (1.65–2.75) 1.61 [1.22, 1.83]
Non-specific sepsis 3.00 (2.92–3.09) 2.28 [1.73, 2.58]
Pneumococcal sepsis 1.17 (1.00–1.37) 0.89 [0.67, 1.01]
Otitis media 0.97 (0.94–1.01) 0.74 [0.56, 0.83]
Otitis media with tympanostomy 1.00 (0.95–1.04) 0.75 [0.57, 0.86]
65+ years
IPD 0.66 (0.63–0.69)
Pneumococcal pneumonia 1.08 (1.02–1.13) 0.87 [0.66, 1.03]
Pneumonia (unsp. organism) 1.97 (1.95–1.98) 1.58 [1.21, 1.88]
Empyema 1.49 (1.39–1.61) 1.20 [0.92, 1.43]
Lung abscess with pneumonia 2.44 (1.95–3.06) 1.96 [1.50, 2.33]
Non-specific sepsis 2.06 (2.03–2.09) 1.66 [1.26, 1.97]
Pneumococcal sepsis 1.07 (0.94–1.21) 0.86 [0.66, 1.02]
Otitis media 1.12 (1.07–1.17) 0.90 [0.69, 1.07]
Otitis media with tympanostomy 1.12 (1.07–1.19) 0.90 [0.69, 1.07]
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inpatient pneumonia activity is likely to be higher than
4.3%. The greater than expected benefit of sequential
PCV7/PCV13 programmes may also reflect the contri-
bution of the additional serotypes in PCV13 to pneumo-
nia — especially serotypes 1 and 19A. The development
of the indirect effect will also increase the reduction
observed in the vaccinated age groups.
Reductions in older age groups in pneumonia of un-
specified origin could not be demonstrated, with in-
creases in admissions for J18 observed in all age groups
from 15 years upwards, continuing the trend observed
before the introduction of the PCV7 programme in 2004
[18]. A similar increase in 65+ year olds post-PCV7/
PCV13 implementation has also been reported from
Scotland, accompanied by a reduction in the length of
stay [15]. These changes in older age groups may repre-
sent an increasing trend towards short stay emergency
hospital admissions in an aging population, as suggested
by a National Audit Office report [19]. The increase in
pneumonia admissions in our study persisted even after
taking into account the upward trend in admissions for
the composite control conditions (Additional file 1: Fig-
ure S3). However, the ratio of the IRR for J18 compared
to the IRR for each individual control condition was
closer to 1 when using urinary tract infections as the
control in those aged 65 years and over (Fig. 3); admis-
sions for UTIs in the elderly are likely to be subject to
similar emergency admission practices as acute respira-
tory infections. Few other studies have assessed the in-
direct impact of PCV in older age groups. In the USA, a
Fig. 3 The ratio of incidence rate ratios, plotted on a log scale, for each age group for all eight disease endpoints against the control conditions.
Points below the horizontal line indicate evidence of an impact of the PCV programme on the incidence of that disease endpoint
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reduction in all-cause pneumonia admissions in 65+ year
olds was reported in a study that encompassed post-
PCV7 and PCV13 periods ranging from 7% in 65–74
year olds to 23% in 85+ year olds [20], but this could
not be replicated in a recent analysis from Australia [21]
or in our study. A hospital-based prospective study in
England that used urinary antigen detection methods
showed a reduction in admissions for non-bacteraemic
vaccine-type pneumonia caused by a PCV13 serotype in
65+ year olds similar in magnitude to the reduction in
IPD, confirming the indirect protection against non-
bacteraemic pneumococcal pneumonia [22]. However,
there was little reduction in overall pneumonia admis-
sions, which may reflect serotype replacement, secular
trends in non-vaccine serotypes or changes in the epi-
demiology of other non-pneumococcal pathogens.
We observed a significant reduction of 80% in
pneumococcal pneumonia in children under 2 years of
age (Table 2, IRR column) which was similar to the
reduction in IPD. Since the diagnosis of pneumococ-
cal pneumonia requires evidence of the causative or-
ganism, the correspondence between these two
disease outcomes is to be expected. Reductions in
pneumococcal pneumonia were also observed in other
age groups consistent with the indirect protection ob-
served for IPD [8]. For pneumococcal sepsis, which
includes pneumococcal meningitis and arthritis, sig-
nificant reductions were observed in children under
15 years, with the largest reduction (66%) in children
under 2 years old. The incidence of pneumococcal
sepsis when added to pneumococcal pneumonia was
considerably lower than the incidence of laboratory-
confirmed IPD in all age groups. This is consistent
with a previous study in which we linked laboratory-
confirmed IPD reports with HES admissions and
found that only a minority of laboratory-reported IPD
cases had a specific pneumococcal sepsis or pneumo-
nia code in HES [23], thus highlighting the limitations
in documenting pathogen-specific causes of admission
in HES.
Our results for the impact on empyema (Fig. 1, Table 2)
are comparable to those reported in the USA [24] and
Scotland [25], where the incidence of empyema
increased after the introduction of PCV7 but declined
after PCV13 for children aged < 15 years. This suggests
that empyema is linked to additional serotypes covered
Table 4 The estimated net change in the total number of cases since April 2007 when comparing the observed relative incidence
of each disease endpoint to the observed relative incidence of the composite control
Disease endpoint <2 years 2–4 5–14 15–24 25–44 45–64 65+ Total
IPD –3209 –729 –454 –637 –2202 –4107 –10,790 –22,128
Pneumococcal pneumonia –854 –187 –274 –282 –588 –509 –1917 –4611
Pneumonia (unsp. organism) –11,583 –2651 –5479 294 6067 38,109 251,894 276,652
Empyema –291 –61 –412 –129 299 395 780 581
Lung abscess with pneumonia –2 –14 20 –12 125 183 353 615
Non-specific sepsis 6500 1209 1277 876 4318 17,238 27,253 58,670
Pneumococcal sepsis –1295 –152 –44 –31 –171 –80 –318 –2092
Otitis media –7473 –2302 –17,584 1978 –2638 –5297 295 –37,568
Otitis media with tympanostomy –6391 –3252 –15,922 –980 –1164 –2864 –77 –30,649
Table 3 Age group- and risk group-specific ratios of case ratios (termed adjusted case ratios) for pneumococcal pneumonia and
pneumonia of unspecified causative organism against the control conditions
Pneumococcal pneumonia Pneumonia of unspecified causative organism
Risk Non-risk Risk Non-risk
Raw case
ratio
Adjusted
case ratio
Raw case
ratio
Adjusted
case ratio
Raw case
ratio
Adjusted
case ratio
Raw case
ratio
Adjusted
case ratio
<2 years 0.36 0.18 (0.14–0.25) 0.21 0.19 (0.15–0.25) 1.34 0.67 (0.50–0.92) 0.73 0.67 (0.51–0.87)
2–4 1.58 0.73 (0.58–0.97) 0.41 0.40 (0.32–0.59) 1.74 0.80 (0.64–1.06) 0.84 0.82 (0.67–1.22)
5–14 0.62 0.35 (0.25–0.46) 0.33 0.31 (0.28–0.39) 1.31 0.73 (0.53–0.96) 0.70 0.67 (0.60–0.84)
15–24 0.50 0.35 (0.27–0.50) 0.61 0.51 (0.38–0.72) 2.19 1.52 (1.20–2.19) 1.11 0.93 (0.69–1.30)
25–44 1.15 0.70 (0.59–0.79) 0.73 0.62 (0.45–0.74) 2.23 1.35 (1.15–1.53) 1.15 0.99 (0.72–1.18)
45–64 1.78 0.83 (0.66–0.96) 0.99 0.77 (0.56–0.85) 2.88 1.34 (1.07–1.56) 1.48 1.15 (0.83–1.27)
65+ 1.61 0.77 (0.55–0.99) 0.61 0.61 (0.54–0.71) 2.96 1.41 (1.00–1.82) 1.13 1.13 (0.99–1.31)
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by PCV13 which increased due to serotype replacement
post-PCV7 and is consistent with studies showing that
the three most prevalent serotypes causing empyema are
3, 1 and 19A [23], all of which are covered by PCV13
but not PCV7.
Mixed results were obtained for the other non-specific
disease endpoints. No reductions for non-specific sepsis
were observed with increases both in raw IRRs and IRRs
relative to the composite control in all age groups. This
suggests that these codes do not contain many cases of
occult pneumococcal sepsis, at least not with a predom-
inance attributable to vaccine-type serotypes. With the
exception of children less than 2 years old, the increase
in incidence was greater for the risk groups than the
non-risk group (Additional file 1: Figures S4-S6). The
reasons for this difference are unclear, but they reflect
our findings in Table 3 showing that the greatest in-
creases in incidence for pneumonia were also in the risk
groups. The findings reported from both a Finnish trial
of PCV10 [9] and a post-licensure study [26] in which
large reductions in non-specific sepsis codes were ob-
served in vaccinated children and vaccine-eligible chil-
dren respectively could not be confirmed in this post-
licensure study of a sequential PCV7/PCV13 programme.
Possible reasons for this are differences in coding practices
between the two countries, in serotype distribution of
pneumococcal-attributable sepsis, or in the contribution
of non-pneumococcal pathogens to admissions with a
non-specific sepsis code. The analyses from Finland
excluded laboratory-confirmed IPD cases, but we were
unable to do this due to a lack of common patient identi-
fiers in our HES and laboratory-confirmed IPD surveil-
lance datasets. However, removal of laboratory-confirmed
IPD cases from admissions with a non-specific sepsis
diagnosis should reduce the proportion of such cases
attributable to the pneumococcus and thus the potential
impact of PCV on this disease endpoint. For lung abscess
with pneumonia, the rIRRs against the composite control
and against each control condition individually were less
than one in age groups under 15 years and similar to that
for empyema.
We were unable to detect a large reduction in admis-
sions for all otitis media diagnoses in infants, echoing the
efficacy trials of PCV7 on all-cause otitis media in Finland
[27] and in the USA [28]. For placement of tympanostomy
tubes, which reflects recurrent or more serious otitis
media, the US trial showed a higher efficacy of 20.1% (95%
CI 1.5–35.2%), and late follow-up of the Finnish trial co-
hort to 5 years of age showed an efficacy of 39% (95% CI
4–61%) against tube placements [29]. However, further
follow-up of the Finnish cohort showed no sustained
efficacy between 6 and 13 years of age [30]. Although we
observed reductions in the incidence of otitis media with
tympanostomies in vaccine-targeted cohorts, reductions
were also observed in the older age groups which are
unlikely to be due to the PCV programme. Ear tube
placements for otitis media are uncommon in adults
(Additional file 1: Table S4), and our findings are
therefore difficult to interpret.
Within the risk group analysis the composite control
was essential to use as a benchmark, as shown by the in-
crease in admissions for the unrelated control conditions
in those with risk factors. This may be an artefact due to
better recording of comorbid conditions in the available
HES ICD codes, or a real increase due to changes in
admission practice, but the comparison with the control
conditions allowed adjustment for such secular trends.
The significant reductions in pneumococcal pneumonia
in high-risk individuals of all ages confirms the herd
immunity benefit of the PCV programme in these vul-
nerable groups and that the additional benefit of direct
vaccination is limited [31]. The increase in older individ-
uals in pneumonia of unspecified organism shown in
Table 2 was largely among those in a risk group (Table 3).
This may reflect their greater susceptibility to develop
pneumonia from less pathogenic serotypes that have re-
placed the PCV13 vaccine types in the nasopharynx as
has been shown for IPD in high-risk children [32].
The use of additional ICD codes to identify the out-
comes of interest should increase sensitivity, but it
would likely be at the cost of reduced specificity. The
contribution of additional true positive or false positive
cases when the ICD-10 codes are expanded will likely
vary with age group, disease outcome and time period,
so the effect is unpredictable, as shown by our analyses.
On balance we preferred to restrict our main analyses to
outcomes of interest in the first diagnosis field, as this is
intended to capture the primary reason for admission
and so should maximise specificity.
Our method of assessing the impact of the PCV
programme in England by comparing the IRR for the
outcome of interest with that in control conditions has
some advantages over other methods such as time-series
analyses that have been used to assess the effect of PCV
on pneumonia. The latter method does not take account
of factors other than vaccination that may have resulted
in secular changes in admission, and the results are
sensitive to the model used to fit the pre-and post-
intervention trend lines [33]. Another variation in the
use of control conditions against which to assess the
impact of PCV on pneumonia has recently been evalu-
ated in a methodological study using hospitalisation data
from five countries in the Americas [34]. In that study
the authors derived a composite control by aggregating
pre-vaccination data across 17 disparate ICD-10
chapters plus 20 additional conditions and then assigned
weights to each to generate a "synthetic" composite
control whose pre-vaccination trend best matched
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pre-vaccination pneumonia trends. The post-vaccination
data from the weighted synthetic controls were then
used as a counterfactual against which to assess the im-
pact of PCV. The weights applied to each ICD chapter/
condition varied substantially between the five countries
and within each country by age. In some age groups, the
results were particularly sensitive to the inclusion of spe-
cific codes in the synthetic control. Overall the results
when using a country-specific synthetic control were
somewhat heterogenous between countries, though, in
common with our findings, there was no evidence of a
decline in all-cause pneumonia admissions in older
adults in any country. The synthetic control method is
computationally demanding, especially when dealing
with very large datasets such as the national HES dataset
and does not take account of interventions apart from
vaccination that may have affected the incidence of the
control conditions. Furthermore, a split into subgroups
such as our analysis of risk- and non-risk groups is
harder to achieve. Our results demonstrate that individ-
ual comparisons between the studied diseases and the
constituent conditions of the composite control are in-
formative. For example, when using urinary tract infec-
tions as the control, the increase in admissions for
pneumonia of unspecified organism in adults aged 65+
years was minimised (21% relative increase); both are
common infections in this age group and are likely af-
fected by the same underlying changes in admission
practices. However, when compared to trends for frac-
tures which showed little change in 65+ year olds over
the same period (Additional file 1: Table S7), the relative
increase was maximal (88% increase). Based on the
knowledge of how admission or management practices
have changed in an individual country, it may be more
efficient to select control conditions that will be un-
affected by the PCV programme but similarly affected
by known changes in health service utilisation.
Limitations
Although the HES database has been running prior to
the start of the study period, we were unable to extract
data for episodes prior to April 2004 because patient
identification fields were not available in the data, pre-
cluding identification of repeat admissions in the same
individual. We were therefore only able to assess the im-
pact of PCV7 using 2 years' worth of data prior to its
introduction mid-2006. Our results would be more ro-
bust if additional data prior to April 2004 were able to
be linked to our existing dataset. The HES database does
not include information on any laboratory testing con-
ducted for each individual, so we were unable to confirm
the aetiology of each case.
We identified risk groups using only the information
available within the selected admissions, rather than
examining prior admissions for individuals in the years
before the outcome diagnoses. This may have resulted in
a lower sensitivity for risk group identification. However,
we performed a subanalysis (unpublished) where more
information from the HES dataset was extracted from
previous years on a patient-by-patient basis for a sample
of 1000 patients. Despite being much more work, adding
information from previous years increased the risk group
identification only from just below 80% to just over 90%,
which we deemed acceptable given the purpose of this
analysis.
Another potential limitation is that we did not try to
estimate the impact of PCV7 and PCV13 separately. We
did this because our laboratory-confirmed IPD analyses
showed that the impact of serotype replacement post-
PCV7, particularly in relation to 19A and 7F, which off-
set some of the benefit of PCV7 was mitigated by the
subsequent introduction of PCV13 [8], and thus it was
more informative to focus on the impact of the sequen-
tial PCV7 and PCV13 programme as a whole than each
separately.
Our analysis of the potential change in the case bur-
den for each of the diagnoses of interest may have
underestimated the reported changes in Table 4, as the
initial period from September 2006 through April 2007
was missed due to the use of HES data years.
Our use of five control conditions is a novel approach
in assessing the impact of a pneumococcal vaccination
programme on hospitalised disease outcomes. Our ana-
lysis could be improved if we had used more than five
control conditions and conducted a more comprehen-
sive analysis of the effect of using as controls conditions
that were likely or unlikely to be affected by similar
changes in admission practices as the pneumococcal-
attributable outcomes. However, we were unable to ex-
tract data for more than five control conditions due to
resource limitations, and with data from only 2 pre-PCV
years available to us in HES, we were unable to conduct
further investigations into the similarities between the
control conditions and the disease outcomes of interest
beyond the age distributions of cases and not being sub-
ject to other public health interventions (see Additional
file 1: Figures S1 and S2). Furthermore, we did not assess
the seasonality of the control conditions. However, we
minimised the impact of seasonality by averaging over a
24-month period and including the same months pre-
and post-PCV (April to March) for both outcomes of
interest and control conditions. Despite being restricted
to five controls, our analysis is an improvement on im-
pact analyses that use no controls or the use of a single
control condition which can be sensitive to changes in
secular trends unrelated to the introduction of the PCV
programme and therefore a source of bias in programme
impact estimates [34].
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We have reported disease trends for many age groups
and many diagnoses of interest, so it is possible that our
results may include some IRR estimates for which the
upper 95% confidence is less than one by chance. How-
ever, a formal correction for multiple comparisons is not
straightforward in this instance given the method that
we have used. Furthermore use of only five controls in
deriving rIRRs precluded any formal statistical compari-
son such as computation of confidence intervals, so
uncertainty in this measure could only be depicted by
showing maximum and minimum rIRR values across the
control conditions.
It is also important to note that the overall burden of
non-invasive pneumococcal disease will be determined
not only by the impact of the PCV programme on
disease caused by the pneumococcus but also by the
epidemiology of other causative pathogens for pneumo-
nia. Changes in the latter may mask an overall reduction
in pneumococcal-attributable non-invasive disease, but
this cannot be assessed by the type of impact assessment
conducted here.
Conclusions
By comparing the incidence of pneumococcal outcomes
with unrelated conditions, and stratifying by risk group
status, our method can help control for the effect of
unrelated secular trends in admissions and help
elucidate the impact of PCV in vulnerable population
groups. Since the beginning the PCV programme, we
observed a substantial reduction in all age groups for the
hospitalised burden of pneumococcal pneumonia; for
children under 15 we observe a decline in pneumonia
with unspecified causative organism and pneumococcal
sepsis, and for those under 2 years a reduction in otitis
media with tympanostomies. For some age groups we
observed increases in the disease burden which could be
non PCV-related or due to replacing serotypes.
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